The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.
 
Soumyajit Roy
Employment - Artera (I); Rush University
Research Funding - Swim Across America
 
Shawn Malone
No Relationships to Disclose
 
Yilun Sun
No Relationships to Disclose
 
Christopher J.D. Wallis
Honoraria - Bayer; EMD Serono; Haymarket Medical Education; Knight Therapeutics; Tersera; Tolmar
Consulting or Advisory Role - Janssen Oncology; Precision Point Specialty; Sesen Bio
Research Funding - Knight Therapeutics
Travel, Accommodations, Expenses - Tolmar
 
Amar Upadhyaya Kishan
Stock and Other Ownership Interests - ViewRay
Honoraria - Boston Scientific; Janssen Oncology; Varian Medical Systems; ViewRay; ViewRay
Consulting or Advisory Role - Boston Scientific; Janssen
Research Funding - Janssen Oncology (Inst); Point Biopharma (Inst); ViewRay; ViewRay
 
Scott C. Morgan
Research Funding - Knight Therapeutics (Inst)
 
Georges Gebrael
No Relationships to Disclose
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Angela Jia
Consulting or Advisory Role - Myovant Sciences
Travel, Accommodations, Expenses - Myovant Sciences
 
Jason R Brown
Honoraria - AstraZeneca
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst)
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Daniel Eidelberg Spratt
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Boston Scientific; Janssen Oncology; Myovant Sciences; Pfizer; Varian Medical Systems
Research Funding - Janssen (Inst)